Biocon Launches Haselmeier’s Insulin Pen in India

Zurich, Switzerland, November 22, 2011 / B3C newswire / -Haselmeier has announced that Biocon, one of Asia’s premier biotechnology companies, has launched INSUPen® in India. Under the terms of the agreement between the two companies, Biocon has worldwide distribution rights to INSUPen®, for use with Biocon’s insulin and insulin analogues.The first launch of the INSUPen® has taken place with Biocon’s Basalog® and Insugen® insulins.

The INSUPen®is a reusable insulin pen based on Haselmeier’s popular i-pen technology. It is designed to be easy to use for the patient and provide accurate and reliable dosing. The INSUPen® is available in 3 attractive colors and is currently custom designed for use with both Basalog® and Insugen®, thus maximizing patient convenience.

The INSUPen® provides diabetic patients an attractive pen with user-friendly features at an affordable cost. Haselmeier is proud to work with Biocon, a premier biotechnology company, on this important program to develop and supply INSUPen®and we look forward to a long and successful partnership,” said Volker Wirth, Director Business Development & Marketing at Haselmeier.

Rakesh Bamzai, President, Marketing at Biocon added: “I am confident that INSUPen® will be a delight for patients and a value enhancer for all stakeholders.”

About Haselmeier GmbHHaselmeier is a leading designer and manufacturer of pen and auto-injection systems. The Company’s devices feature unique function, design and technology and are marketed by leading pharmaceutical and biotechnology companies around the world. For more information visit: www.Haselmeier.com

About Biocon LimitedEstablished in 1978, Biocon Limited (BSE code: 532523, NSE Id: BIOCON, ISIN Id: INE376G01013) is India's largest biotechnology company by revenue. The Group, promoted by Ms. Kiran Mazumdar-Shaw, is a fully-integrated, innovation-driven healthcare enterprise with strategic focus on biopharmaceuticals and research services. Biocon’s value chain traverses the entire length of discovery, development and commercialization of novel therapeutics. With successful initiatives in clinical development, bio-processing and global marketing, Biocon delivers products and solutions to partners and customers in approximately 75 countries across the globe. Many of these products have USFDA and EMA acceptance. Biocon’s robust product offering includes the world’s first Pichia-based recombinant human Insulin, INSUGEN® and India’s first indigenously produced monoclonal antibody BIOMAb-EGFR(TM).